This article presents a summary of results from a recent survey of readers and other experts regarding pharma social media moderation best practices.
Welcome to the MARCH 2010 issue of Pharma Marketing News.
This article presents an overview of the types of organizations that submitted comments versus those that made presentations at the November 2009 public hearing. It also includes general comments from the pharma industry regarding the process by which the FDA should regulate the Internet and social media. Also presented in this article are the comments submitted by consumer advocates and individuals who generally supported more strict regulation across the board.
This article presents a summary of comments to FDA from the drug industry addressing regulatory concerns when using social media tools associated with space limitations or tools that allow for real-time communications to present product information.
In an online webinar entitled 'Reputation Strategies That Drive Results: Turning Your Good Name into Good Business' Kantar Health explored the value of corporate reputation and corporate social responsibility from a traditional channel and digital media perspective and also from the view of understanding how this impacts the relationship between pharmaceutical and Key Opinion Leaders. This article summarizes the presentations made at that webinar.
This is the first in a series of articles summarizing highlights from a recent webinar focused on getting market research right in emerging markets. It features experts from Kantar Health, a global consultancy and marketing insights organization that was formed in 2009 by uniting Consumer Health Sciences, MattsonJack, TNS Healthcare and Ziment.
Welcome to the APRIL 2010 issue of Pharma Marketing News.
Welcome to the DECEMBER 2010 issue of Pharma Marketing News. This is the Executive Summary. This executive summary includes links to ALL the DECEMBER 2010 articles.
Welcome to the NOVEMBER 2010 issue of Pharma Marketing News. This is the Executive Summary. This executive summary includes links to ALL the NOVEMBER 2010 articles.
This article reviews the Who, What, and Why of Pharma's Social Media Working Group (SMWG) based on a conversation with Mark Gaydos, Senior Director, U.S. Regulatory Affairs Marketed Products at sanofi-aventis, and Cynthia Phillips, Sr Dir Labeling and Promotional Compliance at Millennium Pharmaceuticals. Also covered is an analysis of comments the SMWG submitted to the FDA on how pharmaceutical companies should handle off-label and adverse event posts made on social media sites owned or sponsored by them.